Regeneron Pharmaceuticals, Inc. Share Price and Company Fundamentals



Price
$507.14
Change
5.950 (1.187%)
52 week
441.0 - 664.64

Last traded: Last Wednesday at 8:00 PM

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and Biomedical Advanced Research Development Authority. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Key Metrics

PE ratio

16.62

PB ratio

4.78

Dividend yield

Beta

0.19

Market cap

$54.02B

Enterprise value

$49.65B

Company profile

Industry / SectorBiotechnology / Healthcare
Full time employees9123
Websitehttp://www.regeneron.com
Mailing address777 Old Saw Mill River Road Tarrytown NY 10591-6707 United States
Phone / Fax914 847 7000 /

Dividends

Regeneron Pharmaceuticals, Inc. does not pay dividends.

Company Executives

As of May 2021, following are the company executives and directors listed on Regeneron Pharmaceuticals, Inc..

NameTitleAgeTotal Pay
Dr. Leonard S. SchleiferCo-Founder, Pres, CEO & Exec. Director675.35M
Dr. George D. YancopoulosCo-Founder, Pres & Chief Scientific Officer & Director604.38M
Mr. Robert E. Landry Jr.Exec. VP of Fin. & CFO561.79M
Dr. Andrew J. MurphyExec. VP of Research621.64M
Mr. Daniel P. Van PlewExec. VP and GM of Industrial Operations & Product Supply471.79M
Ms. Patrice GiloolySr. VP of Quality Assurance & Operations
Mr. Christopher R. FenimoreSr. VP, Head of Accounting & Controller49
Mr. Gerald UnderwoodSr. VP of Technical Operations
Mr. Bob McCowanSr. VP of IT & Chief Information Officer
Justin HolkoVP of Investor Relations

Profitability and management effectiveness

Profit margin

42.28%

Operating margin

39.65%

Return on assets

12.88%

Return on equity

31.77%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Regeneron Pharmaceuticals, Inc. is 54.02B and its enterprise value is 49.65B. The enterprise value to revenue ratio of REGN is 5.97.

The REGN's stocks Beta value is 0.19 making it 81% less volatile compared to NASDAQ market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Frequently Asked Questions

1. What is Regeneron Pharmaceuticals, Inc.'s Stock Symbol?

Regeneron Pharmaceuticals, Inc. trades on NASDAQ under the ticker symbol "REGN".

2. What is Regeneron Pharmaceuticals, Inc.'s stock price today?

One share of REGN stock can currently be purchased for approximately $507.14.

3. How can I contact Regeneron Pharmaceuticals, Inc.?

Regeneron Pharmaceuticals, Inc.'s mailing address is 777 Old Saw Mill River Road Tarrytown NY 10591-6707 United States. The company can be reached via phone at 914 847 7000.

4. What is Regeneron Pharmaceuticals, Inc.'s official website?

The official website of Regeneron Pharmaceuticals, Inc. is http://www.regeneron.com.